{"filings":[{"id":861917,"accession_number":"0001062993-26-003060","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2026-06-04T20:30:57+00:00","items":["5.07","9.01"],"status":"ready","headline":"Medicus Pharma shareholders approve up to 50:1 reverse stock split at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ratified KPMG as auditor for FY 2026: 28,308,860 for, 756,378 withhold.","All nine director nominees elected; broker non-votes of 13,529,765 per nominee.","Special resolution for reverse share split up to 50:1 passed with 26,729,776 for, 2,335,461 against.","Board now authorized to implement consolidation if deemed necessary for listing requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":697078,"accession_number":"0001062993-26-002900","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2026-05-27T20:45:00+00:00","items":["1.01","2.03","3.01","9.01"],"status":"ready","headline":"Medicus Pharma closes $22M secured notes with Streeterville; receives Nasdaq MVLS non-compliance notice","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued two secured promissory notes to Streeterville Capital: A-1 ($12.86M principal, net $12M) and B ($10M in DACA), maturing in 18 months.","A-1 Note carries 8.75% interest and $834K OID; B Note 5% interest. Prepayment premiums of 110-115% apply.","Proceeds support clinical development, strategic initiatives, and repayment of $2.5M YA II PN debenture.","Nasdaq notified non-compliance with $35M MVLS requirement; company has 180 days to regain compliance by Nov 16, 2026.","B Note can be exchanged for A Notes when A principal reduced by $2M; trigger events allow balance increases of 15%/5%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97109,"accession_number":"0001062993-26-002142","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["1.01","3.01","9.01"],"status":"ready","headline":"Medicus Pharma receives Nasdaq bid price deficiency notice; expands ATM to $50M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Medicus on April 21, 2026 that its stock bid price closed below $1.00 for 30 consecutive business days, non-compliant with Listing Rule 5550(a)(2).","Company has 180 days (until Oct 19, 2026) to regain compliance by closing at $1.00+ for 10 consecutive days.","Medicus increased ATM offering amount from ~$15.35M to $50M via Amendment No. 1; ~$11.5M already raised under the program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111620,"accession_number":"0001062993-26-001326","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Medicus Pharma sells 4.47M shares for $3.85M under Yorkville SEPA through Mar 6, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total of 4,471,038 common shares sold under SEPA from Dec 2025 to Mar 2026 for aggregate $3,846,910.","Largest single draw: 1,425,000 shares on Mar 6, 2026 for approx $640,110.","Proceeds used partly to prepay outstanding debenture with Yorkville (previously disclosed in Sep 2025 8-K).","Yorkville may resell shares under an effective registration statement; additional draws possible subject to SEPA conditions.","Sales rely on Section 4(a)(2) exemption; Yorkville represented itself as an accredited investor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128271,"accession_number":"0001062993-25-017492","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Medicus Pharma enters up to $15.35M ATM equity distribution agreement with Maxim and Yorkville","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM program for aggregate offering of up to $15,349,674 of common shares via Maxim Group and Yorkville Securities.","Commission of 3.0% of gross sales; agents also reimbursed for reasonable expenses.","Sales will be at-the-market on Nasdaq Capital Market; no obligation to sell any shares.","Shares to be issued under new S-3 registration statement filed December 29, 2025, pending SEC effectiveness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128270,"accession_number":"0001062993-25-017219","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["1.01","3.02","7.01","1.02","9.01"],"status":"ready","headline":"Medicus Pharma enters $5.1M warrant inducement; issues new warrants for 4M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$5.1M from exercise of 2,680,000 existing warrants at amended price of $1.92/share.","Issued new unregistered Series C/D warrants to purchase 4,020,000 common shares at $2.00, expiring June 5, 2031.","Company agreed to file resale registration statement for new warrant shares within 60 days of agreement.","Also reported SEPA sales of 680,893 common shares for ~$1.5M from Oct 28 to Dec 4, 2025.","Maxim Group LLC acted as exclusive financial advisor; 6.0% cash fee on gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128269,"accession_number":"0001062993-25-017085","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Medicus Pharma appoints Carolyn Bonner as CFO; Jim Quinlan resigns for health reasons","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Quinlan resigned as CFO effective Nov 28, 2025, after medical leave since Sep 12, 2025.","Carolyn Bonner, previously Acting CFO and President, appointed CFO effective Dec 1, 2025; will continue as President.","Bonner's amended employment agreement: annual base salary $395,000, bonus targets escalating from 60% to 100% over five years.","Bonner brings nearly 20 years healthcare/life sciences experience; previously CEO of PCL, Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128268,"accession_number":"0001062993-25-016864","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Medicus Pharma Q3 net loss $16M, pipeline advances with SkinJect and Teverelix","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $16.0M in Q3 2025 vs $2.3M in Q3 2024; R&D $1.7M, G&A $5.0M.","Cash $8.7M at Sep 30, 2025, up from $5.3M; raised $10.4M from financings and warrant exercises.","Phase 2 SKNJCT-003 >75% enrolled; FDA Type C meeting supports 505(b)(2) pathway for D-MNA (BCC).","Completed Antev acquisition (Teverelix, GnRH antagonist) in August 2025; UK approvals for SKNJCT-003 expansion.","Strategic collaboration with Gorlin Syndrome Alliance for expanded access to SkinJect under FDA IND."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128267,"accession_number":"0001062993-25-016179","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Medicus Pharma sells 1.09M shares to Yorkville for $2.53M, repays debenture","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 1,088,048 common shares to Yorkville between Sep 8 and Oct 16, 2025 at prices from $1.80 to $2.77.","Aggregate proceeds of $2,526,364 from the SEPA Advances.","Proceeds used to partially prepay a Yorkville debenture, as disclosed in Sep 18, 2025 8-K.","Yorkville may resell shares under an effective registration statement; further sales possible under SEPA subject to conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145063,"accession_number":"0001062993-25-015700","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Medicus Pharma secures $8M non-dilutive debenture from Yorkville; net proceeds $5.7M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$8M principal, 8% interest, matures Sept 2026; monthly installments of $650k plus accrued interest.","Refinances ~$1.7M existing debt; net proceeds ~$5.7M after discount, fees, and debt repayment.","Proceeds to accelerate Teverelix (GnRH Antagonist) for AURr and high CV risk prostate cancer (~$6B market).","Optional redemption at any time at face value plus interest; Yorkville may force redemption from equity financings (excluding SEPA)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145062,"accession_number":"0001062993-25-015601","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Medicus Pharma CFO James Quinlan takes medical leave; President Carolyn Bonner named Acting CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO James Quinlan began medical leave on September 12, 2025.","Carolyn Bonner, current President, appointed Acting CFO without additional compensation.","Bonner previously served as President & CEO of Parkway Clinical Laboratories (2019-2023).","No family relationships or reportable transactions between Bonner and company officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145061,"accession_number":"0001062993-25-015149","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["2.01","3.02","5.02","8.01","9.01"],"status":"ready","headline":"Medicus Pharma completes Antev acquisition for ~$3M cash + 1.6M shares; up to $65M contingent","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 98.6% of Antev for ~$3.0M cash and 1,603,164 MDCX shares; up to $65M in contingent milestones tied to FDA Phase 2 and NDA approvals.","Antev develops Teverelix, a GnRH antagonist for acute urinary retention and high-CV-risk prostate cancer; targets ~$6B market.","Patrick J. Mahaffy, former Antev chairman and ex-CEO of Clovis Oncology, appointed to board; receives 25,000 stock options at $1.94 vesting quarterly over 12 months.","Consideration shares subject to staggered 210-day lock-up (15% released every 30 days from effective registration; final 10% at 210 days).","Sold 250,000 common shares to Yorkville via SEPA for ~$490,535 net proceeds; proceeds to prepay outstanding debentures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145060,"accession_number":"0001062993-25-014806","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Medicus Pharma: FDA accepts Type C meeting; Phase 2 BCC study >75% randomized; Q2 net loss $6.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA accepted Type C meeting request; written queries submitted, response expected before end of Q3 2025.","Phase 2 SKNJCT-003 randomized >75% of 90 participants; interim analysis showed >60% clinical clearance.","Cash $9.7M at Q2-end, up from $4.0M Q1; raised $11.5M net from financings and warrant exercises.","Q2 net loss $6.2M vs $3.6M YoY; operating expenses $6.0M vs $3.6M YoY.","CFO James Quinlan exercised 145,000 stock options for ~$156,250 in proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145059,"accession_number":"0001062993-25-013468","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Medicus Pharma signs non-binding MoU with HelixNano for thermostable mRNA vaccine development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-binding MoU to combine Medicus' MNA delivery platform with HelixNano's mRNA platform for thermostable infectious disease vaccines.","Parties aim to form a joint venture for co-development and commercialization of thermostable mRNA-based vaccines.","Plan a Phase 1 bridging study comparing IM injection vs. intradermal MNA delivery of HelixNano's vaccine candidate HN-0001.","Preliminary activities include a Sponsored Research Agreement with University of Pittsburgh (Dr. Lou Falo), supply of HN-0001, and loading into Medicus' MNAs.","MoU is non-binding; no obligation to proceed with joint venture until definitive agreements are executed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145058,"accession_number":"0001062993-25-013266","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Medicus Pharma hires Deloitte to find out-licensing partner for D-MNA (BCC)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deloitte appointed exclusive lead financial adviser for out-licensing D-MNA for basal cell carcinoma.","Company will pay Deloitte retainer plus contingent success fee if a transaction closes.","Engagement letter signed July 29, 2025; no partner identified yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145057,"accession_number":"0001062993-25-013073","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Medicus Pharma adds former Congresswoman McMorris Rodgers and Ajay Raju to board, all shareholder proposals passed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["All eight director nominees elected at July 22 meeting; new board members are Hon. Cathy McMorris Rodgers and Ajay Raju.","Shareholders approved all five proposals: auditor ratification, by-law quorum increase to 33⅓%, Nasdaq 20% Rule share issuance, and 75% board vote to remove Chairman.","Ajay Raju provided $8M seed investment in pre-IPO round; now serves as Chairman/CEO of Raju LLP and co-founder of Avstera Therapeutics.","Cathy McMorris Rodgers served as first female Chair of House Energy & Commerce Committee; retired from Congress in 2024.","Dr. Raza Bokhari continues as Executive Chairman and CEO; company focused on clinical-stage pharmaceutical R&D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145056,"accession_number":"0001062993-25-012767","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Medicus Pharma enters warrant inducement for $3.75M gross; also sells $1.52M shares via SEPA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holder exercises 1.34M existing warrants at $2.80; receives 2.68M new warrants at $3.75 expiring in 5 years.","Gross proceeds from warrant exercise ~$3.75M; net used for clinical trials, working capital, and Antev acquisition costs.","Company sold 490,000 common shares to Yorkville via SEPA for net proceeds of ~$1.52M at ~$3.10/share.","Maxim Group LLC receives 6.0% cash fee on warrant exercise gross proceeds.","Company to file S-1 registration for resale of new warrant shares within 120 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145055,"accession_number":"0001062993-25-012533","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K/A","filed_at":"2025-07-03T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Medicus Pharma signs share exchange agreement to acquire Antev Limited","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Agreement to acquire all Antev Shares; Antev becomes wholly-owned subsidiary of Medicus.","Consideration includes Purchaser Shares (Consideration Shares) and Contingent Consideration tied to milestones.","Antev's lead candidate Teverelix (for acute urinary retention) referenced in forward-looking statements.","Closing expected 3 Business Days after conditions satisfied; drag-along provisions apply for all shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163445,"accession_number":"0001062993-25-012231","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Medicus Pharma to acquire Antev Ltd. for ~17% equity stake + up to $65M contingent milestone payments","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Medicus will issue 2,666,600 common shares (~17% of outstanding) to acquire all Antev shares on a fully diluted basis.","Antev shareholders eligible for up to $65M in contingent consideration tied to FDA Phase 2 and NDA approvals for Teverelix.","Transaction expected to close before end of August 2025, subject to Antev shareholder approval and other conditions.","Antev's lead asset Teverelix targets two indications: acute urinary retention (Phase 2b) and high-CV-risk advanced prostate cancer (Phase 2b).","Consideration shares subject to 9-month staggered lock-up and 36-month voting agreement with Medicus management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163444,"accession_number":"0001062993-25-012044","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Medicus Pharma appoints Andrew Smith COO; Phase 2 BCC trial randomized >50 of 90 patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Andrew Smith appointed COO effective June 30, 2025; base salary $325K, 100k stock options at $2.60 vesting quarterly over 5 years.","Phase 2 SKNJCT-003 for BCC using D-MNA has randomized >50 of 90 patients across 9 US sites; interim analysis showed >60% clinical clearance (preliminary).","Clinical expansion: European sites plus UAE study SKNJCT-004 (36 patients, 4 sites); Cleveland Clinic Abu Dhabi as PI.","Previously announced binding LOI to acquire Antev Ltd. for Teverelix GnRH antagonist; no new terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163443,"accession_number":"0001062993-25-011991","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Medicus Pharma issues third debenture for $2.5M, completing $5M Yorkville facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["On June 17, 2025, issued third debenture to YA II PN, Ltd. for $2.5M principal, net proceeds $2.25M.","Total aggregate principal from three debentures now $5M; net proceeds to Company $4.5M.","Debentures bear 8% annual interest (18% upon default), mature February 2, 2026, guaranteed by subsidiaries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163442,"accession_number":"0001062993-25-011051","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Medicus Pharma dismisses EisnerAmper, engages KPMG as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed EisnerAmper on June 3, 2025; engaged KPMG on June 4, 2025.","EisnerAmper's 2024 audit report included a going-concern qualification.","Material weaknesses in internal controls identified; no restatement occurred.","No disagreements on accounting principles or practices with EisnerAmper.","KPMG appointed as independent auditor for the fiscal year ending Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163441,"accession_number":"0001062993-25-010687","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Medicus Pharma prices $7M public offering of 2.26M units at $3.10/unit; closes June 2","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $7,006,000 from 2,260,000 units at $3.10/unit; each unit = 1 common share + 1 warrant.","Warrants exercisable at $3.10/share, expire 5 years from issuance; not listed on exchange.","Net proceeds to fund Phase 2 proof-of-concept trial for basal cell carcinoma using doxorubicin tip loaded dissolvable microarray needle skinpatch.","Co. also issued $1.25M second-tranche debenture to Yorkville on June 2, 2025, bringing total Yorkville debentures to $2.5M.","Placement agents Maxim, Brookline, D. Boral; cash fee 7.5% of gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163440,"accession_number":"0001062993-25-008436","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Medicus Pharma issues up to $5M debentures to Yorkville at 8% interest, 90% of face value","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial closing of $1.25M debentures; two additional tranches of $1.25M and up to $2.5M subject to conditions.","Debentures bear 8% annual interest (up to 18% upon default), mature Feb 2, 2026, repayable in six monthly installments of $500K each.","Issued at 90% of principal amount; optional redemption by Company, and Yorkville may require redemption with equity financing proceeds.","Subsidiaries provide global guaranty for obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163439,"accession_number":"0001062993-25-008086","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Medicus Pharma (MDCX) to acquire Antev Ltd. in share exchange; up to $65M in milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Consideration: 2,666,600 Medicus shares (~19% stake) plus up to US$65M contingent on FDA Phase 2/NDA approvals.","Antev's lead asset Teverelix is a next-generation GnRH antagonist targeting acute urinary retention recurrence and high-CV-risk prostate cancer.","Combined market opportunity estimated at ~$6B annually ($2B AUR, $4B prostate cancer).","Transaction expected to close by end of June 2025, subject to due diligence, definitive agreement, and regulatory approvals.","Antev shares subject to 9-month staggered lock-up and 36-month voting rights in favor of Medicus management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181368,"accession_number":"0001062993-25-006170","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Medicus Pharma cancels annual/special shareholder meeting scheduled for May 22, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Odyssey Trust Company filed an amendment canceling the previously set meeting date of May 22, 2025 and record date of April 22, 2025.","No new meeting date or record date has been announced; reason for cancellation not disclosed.","The cancelled meeting was to include annual general and special business for shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181367,"accession_number":"0001062993-25-005954","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Medicus Pharma sets annual meeting for May 22, 2025; record date April 22","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual and special meeting of shareholders scheduled for May 22, 2025.","Record date for notice and voting set as April 22, 2025.","Common shares (MDCX) entitled to vote; ISIN CA58471K2020.","Proxy materials not sent directly to non-objecting beneficial owners.","Odyssey Trust Company filed the notice as agent for the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181366,"accession_number":"0001062993-25-005105","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Medicus Pharma closes $4.2M Reg A offering of 1.49M units at $2.80/unit","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Gross proceeds $4,172,000 from 1,490,000 units (one share + one warrant) priced at $2.80/unit; closed March 10, 2025.","Warrants exercisable at $2.80/share for 5 years from issuance; not listed on any exchange.","Net proceeds to fund Phase 2 proof-of-concept trial for basal cell carcinoma using doxorubicin microarray needle patch.","Maxim Group LLC lead placement agent; customary 7.5% cash fee plus expense reimbursement.","Offering qualified under Tier II Regulation A on March 6, 2025; subscription agreement with a single investor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181365,"accession_number":"0001062993-25-002033","cik":1997296,"company_name":"Medicus Pharma Ltd.","ticker":"MDCX","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Medicus Pharma enters $15M equity purchase agreement with Yorkville; plans TSXV delisting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Standby Equity Purchase Agreement with Yorkville for up to $15M over 36 months; shares sold at 97% of market price.","Proceeds to fund Phase 2 BCC trial, expand to pivotal trial and other non-melanoma skin diseases.","Yorkville received $25k structuring fee and 105,840 commitment shares.","Board approved voluntary delisting from TSXV; shares continue on Nasdaq (MDCX).","Drawdowns require effective SEC registration statement; 19.99% cap and 4.99% beneficial ownership limit apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":17479043.71232877,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}